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The effect of minor H antigen mismatching on the occurrence of graft-versus-host disease (GvHD) and graft-
versus-leukemia (GvL) after HLA-matched hematopoietic stem cell transplantation (HSCT) has mainly been
demonstrated in single-center studies. Yet, the International Histocompatibility and Immunogenetics
Workshops (IHIW) provide a collaborative platform to execute crucial large studies. In collaboration with 20
laboratories of the IHIW, the roles of 10 autosomal and 10 Y chromosomeeencoded minor H antigens were
investigated on GvHD and relapse incidence in 639 HLA-identical related donor (IRD) and 210 HLA-matched
unrelated donor (MUD) HSCT recipients. Donor and recipient DNA samples were genotyped for the minor H
antigens HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-2, SP110, PANE1, UGT2B17, and HY. The correlations with
the primary outcomes GvHD (acute or chronic GvHD), survival, and relapse were statistically analyzed. The
results of these multicenter analyses show that none of the HLA class Ierestricted HY antigens were found to
be associated with any of the primary outcomes. Interestingly, of the HLA class IIerestricted HY antigens
analyzed, HLA-DQ5 positive recipients showed a signiﬁcantly increased GvHD-free survival in female-to-male
HSCT compared with male-to-female HSCT (P ¼ .013). Yet, analysis of the overall gender effect, thus inde-
pendent of the known HY antigens, between the gender groups demonstrated an increased GvHD incidence
in the female-to-male transplantations (P < .005) and a decreased GvHD-free survival in the female-to-maleedgments on page 1252.
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Patient and Donor Demographics
Characteristic
Age, mean (standard error), yr
Recipient
Donor
Donor type
Identical related
Matched unrelated
Underlying disease
Acute leukemia
Chronic leukemia
Lymphoma
Plasma cell disorders
Solid tumors
MDS/MPS
Bone marrow aplasia
Inherited disorders
Hemoglobinopathies
Other/not reported
Stem cell source
Bone marrow
Peripheral blood
Cord blood
Other/not reported
MDS indicates myelodysplastic
syndrome.
Data presented as n (%) unless othtransplantations (P < .001). Of all autosomally encoded minor H antigens, only mismatching for the broadly
expressed minor H antigen HA-8 increased the GvHD incidence in IRD HSCT (Hazard ratio [HR] ¼ 5.28, P <
.005), but not in MUD HSCT. Most striking was the inﬂuence of hematopoietic restricted minor H antigens on
GvL as mismatching for hematopoietic minor H antigens correlated with lower relapse rates (P ¼ .078), higher
relapse-free survival (P ¼ .029), and higher overall survival (P ¼ .032) in recipients with GvHD, but not in
those without GvHD. In conclusion, the signiﬁcant GvHD effect of the broadly expressed minor H antigen HA-
8 favors matching for HA-8 in IRD, but not in MUD, patient/donor pairs. The GvHD-GvL association
demonstrating a signiﬁcant lower relapse in hematopoietic minor H antigen mismatched patient/donor pairs
underlines their clinical applicability for adoptive immunotherapy, enhancing the GvL effect in a GvHD
controllable manner.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION GvHD in blood [11] and skin samples of male patients after
Minor histocompatibility (H) antigens are considered to
play a key role in the allo-immune responses after HLA-
matched stem cell transplantation (HSCT), evoking graft-
versus-host disease (GvHD) and the curative reaction
designated as graft-versus-leukemia (GvL) [1,2]. The cell
and tissue expression of the minor H antigens determine
their participation in GvHD and GvL reactions. Whereas the
hematopoietic-restricted minor H antigens (hematopoietic
minor H antigens) induce important allo-immune responses
in GvL, the broadly expressed minor H antigens
(broad minor H antigens) participate in both GvHD and
GvL [3].
Regarding the latter group of broad minor H antigens,
clinical results show that HLA-matched minor H antigen-
mismatched transplantation recipients have an increased
risk for developing GvHD and a poorer survival. In general,
gender mismatching signiﬁcantly affects HSCT outcome; the
highest risk for GvHD has been observed in male recipients
of female stem cells [4-7]. Mismatching for the broad auto-
somally encoded minor H antigen HA-8 or UGT2B17
increases the risk for GvHD [8,9]. Experimental evidence for
the involvement of broad minor H antigens, such as HY, in
the GvHD arm of HSCT was shown by functional in vitro
assays [3] and by an in situ ex vivo skin explant assay [10].
Importantly, HY-speciﬁc T cells are detectable during clinicalGvHD No GvHD
36.6 (.84) 35.6 (.79)
37.2 (.88) 38.9 (.96)
225 (35%) 414 (65%)
86 (41%) 124 (59%)
131 (39%) 201 (61%)
114 (53%) 102 (47%)
17 (25%) 51 (75%)
7 (16%) 36 (84%)
0 16 (100%)
36 (49%) 38 (51%)
6 (27%) 16 (73%)
0 56 (100%)
0 11 (100%)
0 11 (100%)
225 (42%) 308 (58%)
86 (32%) 184 (68%)
0 1 (100%)
0 45 (100%)
syndrome; MPS, myeloproliferative
erwise indicated.gender-mismatched HSCT [12].
The effect of mismatching for the hematopoietic minor H
antigen HA-1 on GvHD has been studied by several investi-
gators reporting different outcomes. Whereas some studies
observed an association between HA-1 mismatching and the
development of GvHD, others did not [13-16]. A plausible
explanation for the reported association of HA-1 with GvHD,
is the putative presence of recipient’s residual dermal
antigen-presenting cells after HSCT [10,17]. These antigen-
presenting cells reside for various time spans in recipients’
skin [10] and are able to stimulate HA-1-speciﬁc T cells in
ex vivo in situ models [17]. Although not speciﬁcally inves-
tigated for ACC-1, it may also explain the observed correla-
tion between ACC-1 mismatching and GvHD [17].
The main and crucial activity of the hematopoietic minor
H antigens resides in the GvL arm of HSCT. Their
hematopoietic-restricted expression also includes leukemic
cells and leukemic progenitor cells [18]. In vitro experiments
demonstrated lysis of leukemic cells when exposed to cyto-
toxic T lymphocytes (CTLs) speciﬁc for HA-1 and HA-2 [19],
ACC-1 and ACC-2 [20], HB-1 [21], PANE1 [22] and SP110 [23].
Clinically, CTLs speciﬁc for the hematopoietic minor H anti-
gens HA-1, HA-2, and LRH-1 coincide with remission of
hematological malignancies after donor lymphocyte infusion
[19]. The therapeutic potency of the latter minor H antigens
has been demonstrated in animal models [24].
Clinical evidence for GvL effects of hematopoietic minor
H-antigenmismatches is sparse. Two studies reported on the
absence of correlation between HA-1 mismatching and
relapse [25,26]. To the contrary, HA-1 disparity is correlated
with lower leukemia relapse rates in HLA-A2-positive
chronic myeloid leukemia (CML) recipients who received
myeloablative allo-SCT from HLA-identical related donors
(IRD) [15,27]. Moreover, the emergence of HA-1-speciﬁc
cytotoxic T cells parallels the therapeutic effect of donor
lymphocyte infusion [25,28]. Interestingly, a signiﬁcantly
reduced relapse incidence was observed in CML recipients of
HA-1 mismatched HSCT grafts but was restricted to patients
suffering from GvHD [29].
In the present multicenter study, we investigated the
effect of mismatching of 10 autosomally encoded and 10 Y
chromosomeeencoded minor H antigens on the clinical
outcome of 639 HLA-identical related and 210 HLA-matched
unrelated HSCT.MATERIALS AND METHODS
Study Population
A total of 849 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched trans-
plantations, facilitated by the participating centers, were studied. All
materials were obtained after informed consent according to the local
guidelines of the participating centers. Table 1 summarizes all relevant
patient and donor characteristics.
Table 2
Minor H Antigens Included in This Study, Encoded by Genes on the Y Chromosome (A) and on the Autosomal Chromosomes (B)
A
Minor H Antigen HLA Restriction HUGO Gene Name Tissue Distribution
A1/HY A1 USP9Y Ubiquitin speciﬁc peptidase 9, Y-linked Broad
A2/HY A2 KDM5D Lysine (K)-speciﬁc demethylase 5D Broad
A33/HY A33 TMSB4Y Thymosin, beta 4, Y-linked Unknown
B27/HY B27 DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked Restricted
B52/HY B52 RPS4Y1 Ribosomal protein S4, Y-linked 1 Restricted
B60/HY B60 UTY Ubiquitously transcribed tetratricopeptide repeat gene, Y-linked Broad
B7/HY B7 KDM5D Lysine (K)-speciﬁc demethylase 5D Broad
B8/HY B8 UTY Ubiquitously transcribed tetratricopeptide repeat gene, Y-linked Restricted
DQ5/HY DQ5 DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked Broad
DR15/HY DR15 DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked Broad
DRB3*0301/HY DRB3*0301 RPS4Y1 Ribosomal protein S4, Y-linked 1 Broad
B
Chrom. Minor H Antigen HLA Restriction Hugo Gene Name Tissue Distribution
19 HA-1/A2 HLA-A2 HMHA1 histocompatibility (minor) HA-1 Restricted
19 HA-1/B60 HLA-B60 HMHA1 histocompatibility (minor) HA-1 Restricted
7 HA-2 HLA-A2 MYO1G myosin IG Restricted
15 HA-3 HLA-A1 AKAP13 A kinase (PRKA) anchor protein 13 Broad
9 HA-8 HLA-A2 KIAA0020 KIAA0020 Broad
5 HB-1 HLA-B44 HMHB1 histocompatibility (minor) HB-1 Restricted
15 ACC-1 HLA-A24 BCL2A1 B-cell leukemia/lymphoma 2 related protein A1 Restricted
15 ACC-2 HLA-B44 BCL2A1 B-cell leukemia/lymphoma 2 related protein A1 Restricted
22 PANE1 HLA-A3 CENPM centromere protein M Restricted
2 SP110 HLA-A3 SP110 SP110 nuclear body protein Restricted
4 UGT2B17 HLA-A29 UGT2B17 UDP glucuronosyltransferase 2 family, polypeptide B17 Broad
4 UGT2B17 HLA-B44 UGT2B17 UDP glucuronosyltransferase 2 family, polypeptide B17 Broad
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Recipient and donor DNA were genotyped for 10 autosomal minor H
antigens, ie, HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-2, SP110, PANE1,
and UGT2B1, using a PCR-SSP-based assay developed at the Leiden
University Medical Center, as described previously [30]. The minor H
antigen characteristics, their HLA restriction molecules, and the immuno-
genic alleles have been described before [30]. Primers used for minor H
antigen-speciﬁc ampliﬁcation were synthesized and provided by Invitrogen
(Carlsbad, CA).
Deﬁnitions of Outcomes
The primary outcomes of the analysis were overall survival, deﬁned as
time from graft infusion (day 0) to death from any cause, time to acute GvHD
(absence or occurence of acute GvHD; information on GvHD gradingwas not
provided by the participating centers), deﬁned by the Glucksberg scale [31],
time to chronic GvHD, as deﬁned according to the Seattle criteria [32], time
to death after GvHD, and time to non-GvHDerelated mortality. Relapse was
deﬁned as the time from graft infusion to recurrence of the original disease.
Additionally, death after relapse, and nonrelapse-related mortality were
analyzed.
Statistical Analysis
Minor H antigen mismatches of the HSCT pairs were classiﬁed as GvH
mismatched or GvH matched using the dbMinor algorithm (www.lumc.nl/
dbminor) [32]. To investigate the effect of minor H antigen mismatches, the
association between transplantation outcomes and minor H antigen
matched versus minor H antigen mismatched was quantiﬁed by using
a survival framework on the donor/recipient pairs. Cox proportional hazard
analyses were used taking GvHD and death as competing risks. The occur-
rence of death is censored by the occurrence of GvHD (and vice versa) in
complete analogy to the usual analyses of relapse and mortality. The asso-
ciations of HA-3, HA-8, donor type, and hematopoietic minor H antigen
mismatching with transplantation outcome were quantiﬁed by the hazard
ratio in these models. Outcomes were overall survival, GvHD incidence,
GvHD-free survival, and non-GvHD mortality.
Furthermore, GvHD was also treated as a time-dependent risk factor
itself, when analyzing its effect on overall survival, relapse incidence,
relapse-free survival, and nonrelapse mortality. The hazard ratios, therefore,
are always consistent with a competing risk framework and can be used to
compute cumulative incidence curves (except when GvHD is used as a time-
depending covariate).
P values less than or equal to .05 were considered to be statistically
signiﬁcant. In view of the diminished power of statistical test for interac-
tions, we consider the data to indicate interaction (effect modiﬁcation)when the P value is less than or equal to .10, effectively taking 10% as
a signiﬁcance level.
All line graphs in Figures 1, 2, 3, and 4 are cumulative incidence esti-
mates stemming from the above-mentioned Cox models in the usual
framework of competing risks. They are univariate or bivariate estimates
(stratiﬁed) and not based on modeling the curves themselves. Figure 5
integrates the various estimated curves into 1 stacked graph depicting the
estimated proportion of patients in each of the 4 states (equivalent to
a multistate model that corresponds to the competing risk framework).RESULTS
Overall Gender Effect but Little Inﬂuence of Single HY
Antigens on GvHD
Analyses of 7 HLA class I-restricted HY antigens were
carried out on the 7 HY antigens as a group and on each of
them separately. Comparing HSCT pairs with at least 1 or
more HY antigen mismatch versus gender matched pairs
showed no signiﬁcant inﬂuence on GvHD incidence, relapse,
or survival, regardless of the donor type (GvHD in Figure 1A,
Supplementary Table 1).
For separate statistical analysis of HLA-A33/HY, HLA-B52/
HY, and HLA-B60/HY, the number of HY-mismatched HSCT
pairs was too low (Supplementary Table 2). For HLA-B7/HY
and HLA-B8/HY, no differences between the gender-
matched and the gender-mismatched groups were
observed (data not shown). For the HLA-A1/HY, a strong, but
statistically not signiﬁcant tendency towards an increased
GvHD incidence was found (Figure 1B) (HR ¼ 3.0, P ¼ .06),
independent of the donor type (P ¼ .92). For HLA-A2/HY, no
correlation with GvHD incidence was observed, neither in
IRD (HR ¼ 1.5, P ¼ .35), nor in MUD HSCT (HR ¼ .81, P ¼ .64)
(Figure 1C). Cox regression analyses showed a weak inter-
action between HY mismatching and donor type in relation
to developing GvHD for HLA-A2/HY (HR ¼ 2.0, P ¼ .25).
Analyses of the 3 HLA class IIerestricted HY antigens as
a group yielded no signiﬁcant differences (data not shown).
Analyses of the 3 HLA class IIerestricted HY antigens sepa-
rately demonstrated a nonsigniﬁcant increased GvHD
Figure 1. The effect of mismatching for HLA class-I restricted HY minor H antigens on grat-versus-host disease (GvHD) incidence. Blue lines represent the matched
unrelated donor (MUD) recipients, and red lines represent the identical related donor (IRD) recipients. Solid lines are minor H antigen matched and the dotted lines
are minor H antigen mismatched. (A) IRD recipients with 1 or more HY mismatches (dotted red line) show comparable GvHD incidence when compared to IRD
recipients who are fully matched for all HY minor H antigens tested and to MUD recipients (blue line and blue dotted line, respectively). (B) HLA-A1/HY mismatching
increases the GvHD incidence in both IRD and in MUD recipients. (C) Mismatching for HLA-A2/HY affects the GvHD incidence in IRD recipients but not in MUD
recipients. None of these trends were statistically signiﬁcant. See Supplementary Table 1 for detailed statistics.
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compared with HY-matched HLA-DR15 IRD recipients (HR ¼
1.8, P ¼ .19) (Figure 2A). The number of HLA-DR15 MUD
recipientswas too low for adequate analyses. The role of HLA-
DRB3*03:01/HY could not be evaluated, as noneof the centers
reported allelic typing for the HLA-DRB3 locus.
When analyzing the effect of HLA-DQ5/HY on GvHD
incidence, a nonsigniﬁcant trend toward a lower incidence of
GvHD was observed in the female-to-male HSCT pairs as
opposed to the combined HLA-DQ5 gender-matched (ie,
male-to-male and female-to-female) and male-to-female
HSCT pairs (HR ¼ .45, P ¼ .07) (Figure 2B). This trend was
present both in IRD (HR ¼ .41, P ¼ .15) and in MUD HSCTFigure 2. The effect of mismatching for HLA class IIerestricted HY minor H antig
recipients, and red lines represent the identical related donor (IRD) recipients. Solid
mismatched. (A) IRD recipients with an HLA-DR15/HY mismatch (dotted red line) sho
matched. MUD recipients with an HLA-DR15/HY mismatch were not observed in this s
in both IRD and in MUD recipients. (C) Female recipients of a male HLA-DQ5/HY-m
recipients of a female graft.(HR ¼ .50, P ¼ .27). Thus, there was no interaction between
donor type and HY mismatching (data not shown). When
comparing HLA-DQ5 female-to-male pairs with the HLA-
DQ5 male-to-female pairs (Figure 2C), HLA-DQ5 female
recipients (IRD and MUD combined) displayed a statistically
signiﬁcant lower GvHD rate (HR ¼ .30, P < .05). Moreover,
HLA-DQ5 male-to-female HSCT demonstrated a signiﬁcantly
increased GvHD-free survival when compared with
HLA-DQ5 female-to-male HSCT (HR ¼ .037, P < .05). None of
the HLA class IIerestricted HY mismatches correlated with
GvL (data not shown).
The overall gender effect between the gender groups, thus
independent ofHYpresentingHLAclass I or class IImolecules,ens on GvHD incidence. Blue lines represent the matched unrelated (MUD)
lines are minor H antigen matched and the dotted lines are minor H antigen
w a trend to more GvHD incidence when compared to IRD recipients who are
tudy. (B) HLA-DQ5/HY mismatching signiﬁcantly decreases the GvHD incidence
ismatched graft display signiﬁcantly more GvHD when compared with male
Figure 3. The effect of mismatching for broad autosomal minor H antigens on graft-versus-host disease (GvHD) incidence. Blue lines represent the matched
unrelated donor (MUD) recipients, and red lines represent the identical related donor (IRD) recipients. Solid lines are minor H antigen matched and the dotted lines
are minor H antigen mismatched. All statistically signiﬁcant differences are visualized in the graphs. (A) IRD recipients with 1 or more mismatches for the broad
autosomal minor H antigens (dotted red line) show an increased GvHD incidence when compared with IRD recipients who are fully matched for all broad autosomal
minor H antigens tested. These differences were not observed for minor H antigen matched and mismatched MUD recipients (blue line and blue dotted line,
respectively). (B) HA-8 mismatching increases the GvHD incidence in IRD recipients, but not in MUD recipients. (C) Mismatching for HA-3 affects the GvHD incidence
in both the IRD and the MUD groups. See Table 3 for statistics.
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female-to-male transplantations compared with the other
groups combined (HR ¼ 2.45, P < .005) and a decrease of
GvHD-free survival in the female-to-male transplantations
(HR ¼ 2.19, P < .001) (Supplementary Figure 1).
In conclusion, of all single HLA class Ie and IIerestricted
HYantigens analyzed, only the HLA-DQ5 female recipients of
male grafts reached a statistically signiﬁcant interactionwith
higher GvHD-free survival. Overall gender analysis on the
whole study population, regardless of the known HY anti-
gens, showed signiﬁcant higher GvHD incidence and
decreased GvHD-free survival in male recipients of female
grafts.Mismatches for Broad Autosomal Minor H Antigens
Correlate with GvHD
Disparities between HLA-matched recipients and their
donors for broad autosomal minor H antigens, ie, HA-3, HA-
8, and UGT2B17, were analyzed for their impact on GvHD
development, relapse, and recipient survival. In IRD pairs,
mismatching for at least 1 broad autosomal minor H antigen
resulted in a 4-fold increased GvHD risk (HR ¼ 3.93, P < .05)
(Figure 3A). This increased risk was not observed in the MUD
group (HR ¼ 1.18, P ¼ .64).
The increased GvHD risk in the study population was
mainly due to HA-8 mismatching (Table 3; Figure 3B) (HR ¼
3.9, P < .05). Statistical analyses on the interaction between
HA-8 mismatching and donor type (ie, IRD or MUD) in Cox
regression analyses, showed a signiﬁcant effect of HA-8
mismatching in IRD but not in the MUD pairs; Cox regres-
sion analysis resulted in a HR of 5.28 (P < .005) in the IRD
group. Notably, in the IRD group, all recipients of an HA-8-
mismatched graft (n ¼ 5) developed GvHD.
HA-3 mismatching displayed a trend to an increased risk
for GvHD (HR ¼ 3.31, P ¼ .078) (Figure 3C). Moreover, HA-3-
mismatched recipients showed a statistically signiﬁcance of
3-fold decreased GvHD-free survival (HR ¼ .32, P < .05).Interaction analyses (P ¼ .37) did not justify separation of the
IRD group from the MUD group.
The role of mismatches for the minor H antigens
UGT2B17/A29 and UGT2B17/B44 could not be addressed
because of the low numbers of relevant mismatched pairs
(Supplementary Table 3). In summary, of all broad autosomal
minor H antigens analyzed in this study, only the minor H
antigen HA-8 demonstrated a signiﬁcant inﬂuence on the
development of GvHD in IRD but not in MUD trans-
plantations. Analysis of the impact of mismatching on
relapse and recipient survival yielded no signiﬁcant results.
Mismatches for Hematopoietic Autosomal Minor H
Antigens do Not Correlate with GvHD or with GvL
The inﬂuence of mismatching for hematopoietic auto-
somal minor H antigens on GvHD, relapse, and survival was
analyzed. One or more hematopoietic minor H antigen
mismatches within a single HSCT pair did not lead to
a signiﬁcant increase in GvHD incidence neither in the MUD
nor in the IRD pairs (overall HR ¼ 1.075, P ¼ .71) (Figure 2A).
Analysis of each minor H antigen separately showed
a signiﬁcant increase in GvHD in ACC-1-mismatched recipi-
ents of an IRD HSCT (HR ¼ 3.7, P ¼ .05) only, conﬁrming
earlier reports. Individual analyses of all other hematopoietic
minor H antigens yielded no signiﬁcant differences in any of
the outcome parameters between matched and mismatched
groups (data not shown).
The restricted expression of hematopoietic minor H
antigens assumes their effect on the GvL activity. However, in
the present study, the relapse rates in recipients with 1 or
more hematopoietic minor H antigen mismatches were
equal to the relapse rate in recipients matched for all
hematopoietic minor H antigens. These results were similar
both for the IRD and the MUD transplantations (HR ¼ 1.051,
P ¼ .88) (Figure 3B). Equal relapse rates were observed for
HA-1-mismatched and HA-1-matched recipients, as depic-
ted in Figure 3C (IRD: HR ¼ .653, P ¼ .59; MUD: HR ¼ 1.011,
P ¼ .98). Consequently, no correlation was observed between
Figure 4. The effect of mismatching for hematopoietic minor H antigens on graft-versus-host disease (GvHD) and graft-versus-leukemia (GvL) incidence. Blue lines
represent the matched unrelated donor (MUD) recipients, and red lines represent the identical related donor (IRD) recipients. Solid lines are minor H antigen
matched and the dotted lines are minor H antigen mismatched. None of the differences are statistically signiﬁcant. (A) Recipients with 1 or more mismatches in the
hematopoietic minor H antigen (dotted lines) show no increased GvHD incidence when compared with recipients who are fully matched for all hematopoietic minor
H antigens tested, neither in the IRD group (red), not in the MUD group (blue). (B) Recipients with at least 1 mismatch for a hematopoietic minor H antigen (dotted
lines) show no decreased relapse incidence when compared to recipients who are fully matched for all hematopoietic minor H antigens tested, neither in the IRD
group (red), nor in the MUD group (blue). (C) HA-1 mismatching had no effect on relapse incidence.
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relapse in either donor type.
Mismatches for Hematopoietic-Restricted Autosomal
Minor H Antigens Correlate with GvL in Recipients with
GvHD
We earlier demonstrated the GvHD-dependent effect of
HA-1 mismatching on relapse [29]. In the latter study, GvHD
was analyzed as a static parameter and comprised only CML
patients. In the present study, the role of GvHD on the relapse
incidence was analyzed as a time-dependent risk factor,
comparing all recipients with 1 or more hematopoietic
minor H antigen mismatches with the pairs matched for all
studied hematopoietic minor H antigens. Moreover, we here
analyzed all patients, regardless of the underlying disease.
Table 4 lists the effect of hematopoietic minor H antigen
mismatching on relapse incidence (HR ¼ .30, P ¼ .078),
relapse-free survival (HR¼ .347, P< .05), and overall survival
(HR ¼ .315, P < .05); all signiﬁcantly dependent on the
presence of GvHD. As time-dependent Cox regression anal-
yses cannot be depicted graphically, we illustrated these
effects via incidence curves with GvHD as a static parameter
(Figure 5). Note that this depiction cannot be envisaged as
a predictive model, but only describes our data set. The
incidence curves support the above-observed lower relapse,
improved relapse-free survival, and better overall survival in
hematopoietic minor H antigen-mismatched recipients with
GvHD when compared with those without GvHD for IRD
HSCT recipients (Figure 5E versus Figure 5G). The majority
(82%) of the patients with GvHD and a hematopoietic minor
H antigen mismatch (Figure 5G) survive free of relapse; the
ﬁrst relapse in this group was observed only after 23 months
in 1 patient and 25 months after HSCT in the second. One of
the latter patients died 28 months after HSCT.
No correlations with reduced relapse rates were observed
in the hematopoietic minor H antigen-matched groups
(Figure 5A versus Figure 5C). The occurrence of GvHD did not
inﬂuence the effect of matching/mismatching on relapse, onrelapse-free survival, on nonrelapse mortality, and on overall
survival in the MUD recipients (Figure 5B versus Figure 5D,
Figure 5F versus Figure 5H). Our data set did not allow
statistical analysis of a triple interaction analysis including
donor type, minor H antigen mismatching, and GvHD status.
In summary, hematopoietic minor H antigens signiﬁcantly
inﬂuence the GvL effect in patients suffering from GvHD.
Data sets were too small to reliably analyze this effect
for each hematopoietic minor H antigen separately
(Supplementary Table 3).
DISCUSSION
This multicenter study, comprising 639 IRD and 210 MUD
HSCT pairs, investigated the effect of minor H antigen mis-
matching on HSCT outcome. This comprehensive study
yields thorough insights in the role of 10 autosomally and 10
Y chromosomeeencoded minor H antigens in GvHD, GvL
effect, and overall survival.
Most HY antigens included in our study showed a broad
tissue distribution (Table 2A). Consequently, an effect of HY
mismatching on the outcome of HSCT can be expected. A
previous report suggested that the effects of gender mis-
matching on GvHD are mainly conﬁned to patients surviving
more than 6 months after transplantation, leading to an
increased relative risk for chronic but not acute GvHD [33].
Although the numbers in the current study are too low to
analyze these late effects, this phenomenon seems to be
absent when analyzing the HLA class I-restricted HYantigens
as a group, as displayed by the virtually overlapping curves in
Figure 1A. Whether or not the HLA-A2/HY shows an effect in
IRD recipients, as suggested by the divergence of the GvHD
incidence curves in Figure 1C, remains to be elucidated in
larger cohorts. Likewise the HLA class I-restricted HY anti-
gens, our data of the HLA class IIerestricted HY antigens
revealed, with 1 exception, no signiﬁcant correlations with
themeasured clinical parameters. The 1 correlation observed
was found for HLA class II DQ5/HY. Namely, HLA-DQ5/HY
mismatching in the female-to-male HSCT resulted in
Figure 5. Effect of hematopoietic minor H antigen disparity on all outcome parameters, depending on the graft-versus-host disease (GvHD) status, assuming GvHD as
a time-independent risk factor. All curves estimated in a competing risk framework; the 4 panels arise from ﬁtting a competing risk model on each of the 4 subgroups
separately (ie, 4 univariate analyses without further model assumptions apart from the competing risks framework). Note that these ﬁgures do not correctly predict
the outcome correctly, as GvHD must be regarded as a time-dependent risk factor (see Table 4 for the correct statistics). Blue area: non-relapse-related mortality. Red
area: dead after relapse; Yellow area: alive after relapse. The remaining green area represents the relapse-free survival. Left row: identical related donor (IRD); Right
row: matched unrelated donor (MUD). A) hematopoietic minor H antigen-matched IRD in recipients without GvHD; B) hematopoietic minor H antigen-matched
MUD in recipients without GvHD; C) hematopoietic minor H antigen-matched IRD in recipients with GvHD; D) hematopoietic minor H antigen-matched MUD in
recipients with GvHD; E) hematopoietic minor H antigen-mismatched IRD in recipients without GvHD; F) hematopoietic minor H antigen-mismatched MUD in
recipients without GvHD; G) hematopoietic minor H antigen-mismatched IRD in recipients with GvHD; H) hematopoietic minor H antigen-mismatched MUD in
recipients with GvHD.
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compared with male-to-female HSCT. Although intriguing,
we currently have no explanation for the latter correlation.
Our analyses on all study objects of an overall gender effect,
thus independent of the known HY antigens, conﬁrmed the
known detrimental inﬂuences of female grafts to male
recipients on the GvHD incidence (P < .005) and on GvHD-
free survival (P < .001). Whether or not parity of the
female donors inﬂuenced these results is unknown; our data
set lacks that speciﬁc information.
Like most of the molecular identiﬁed HY antigens, the
autosomally encoded minor H antigens HA-3, HA-8, and
UGT2B17, show broad tissue distribution. Therefore, theirpossible impact on GvHD was investigated in the underlying
study as well. Moreover, the effect of minor H antigen
mismatching is assumed to be most pronounced in the HLA
identical HSCT setting as opposed to the (partially) HLA-
matched unrelated donor setting [13]. This assumption
was recently demonstrated in separate studies on the effect
of HA-8 mismatching on GvHD in either IRD [8,34] or in
MUD transplantations [16]. Anticipating the latter, we
executed all analyses for both of these donor types. Studying
our large cohort, we demonstrated that the effect of HA-8
mismatching on GvHD is indeed restricted to the IRD
HSCT (P < .05 for interaction between HA-8 mismatching
and donor type). Because MUD pairs are expected to differ
Table 3
Cox Proportional Hazards Regression Analysis of Autosomally-Encoded
Broad Minor H Antigen Mismatches as Risk Factors for Graft-Versus-Host
Disease, Survival, and Relapse
Outcome P Value Hazard Ratio (95%
Conﬁdence Interval)
GvHD incidence
Broad .10 1.61 (.9 to 2.8)
HA-3 .08 3.31 (.9 to 12.5)
HA-3* donor type .37 .27 (0 to 4.8)
HA-3 (IRD) .59 1.87 (.2 to 4.8)
HA-3 (MUD) .09 5.43 (.8 to 38.8)
HA-8 .13 1.63 (.9 to 3.1)
HA-8* donor type <.05 3.93 (1.0 to 15.1)
HA-8 (IRD) <.005 5.28 (1.7 to 16.3)
HA-8 (MUD) .82 1.09 (.5 to 2.4)
GvHD-free survival
Broad .30 1.30 (.8 to 2.1)
HA-3 <.05 3.14 (1.0 to 9.8)
HA-3* donor type .86 .81 (.1 to 8.0)
HA-3 (IRD) .23 2.56 (.6 to 11.9)
HA-3 (MUD) .18 3.39 (.6 to 20.5)
HA-8 .35 1.30 (.8 to 2.3)
HA to 8* donor type .19 2.30 (.7 to 7.9)
HA-8 (IRD) .05 2.82 (1.0 to 8.1)
HA-8 (MUD) .80 1.09 (.6 to 2.1)
Overall survival
Broad .55 .82 (.4 to 1.6)
HA-3 .50 1.74 (.3 to 8.7)
HA-3* donor type .94 81866 (0 to 10134)
HA-3 (IRD) .11 3.81 (.7 to19.8)
HA-3 (MUD) .68 .03 (.1 to 106)
HA-8 .50 .77 (.3 to 1.6)
HA-8* donor type .39 .39 (.1 to 1.9)
HA-8 (IRD) .34 .38 (.1 to 2.8)
HA-8 (MUD) .96 .98 (.4 to 2.3)
Relapse incidence
Broad .33 .04 (0 to 24)
HA-3 .60 .58 (.1 to 4.6)
HA-3* donor type .99 .00 (0 to N)
HA-3 (IRD) .63 .04 (0 to 14,331)
HA-3 (MUD) .59 .54 (.1 to 5.2)
HA-8 .97 1.02 (.4 to 2.9)
HA-8* donor type .97 .00 (0 to 10293)
HA-8 (IRD) .44 .04 (0 to 138)
HA-8 (MUD) .54 1.37 (.5 to 3.8)
Relapse-free survival
Broad .45 .63 (.2 to 2.1)
HA-3 .71 1.28 (.4 to 4.6)
HA-3* donor type .34 3.67 (.3 to 53.7)
HA-3 (IRD) .33 2.171 (.5 to 10.3)
HA-3 (MUD) .59 .54 (.1 to 5.2)
HA-8 .74 .89 (.5 to 1.7)
HA-8* donor type .23 .274 (0 to 2.3)
HA-8 (IRD) .25 .31 (0 to 2.3)
HA-8 (MUD) .69 1.16 (.6 to 2.4)
IRD indicates HLA-identical related donor; MUD, HLA-matched unrelated
donor.
<.05 and <.005 indicate a P value from .01 to .05 and from .001 to .005
respectively.
* Interaction analyses have been performed for these 2 factors. HA-3 and
HA-8 were tested in a univariate model.
Table 4
Cox Proportional Hazard Analyses for Relapse and Survival with GvHD as
a Time-Dependent Risk Factor
Outcome P Value Hazard Ratio (95%
Conﬁdence Interval)
Relapse incidence
Minor H antigen matching .13 1.80 (.846 to 3.848)
Donor type .33 1.32 (.754 to 2.307)
GvHD .86 .94 (.482 to 1.834)
Minor H antigen matching* GvHD <.10 .30 (.078 to 1.146)
Relapse-free survival
Minor H antigen matching .27 1.37 (.784 to 2.403)
Donor type .64 1.40 (.747 to 1.604)
GvHD .77 1.07 (.689 to 1.654)
Minor H antigen matching* GvHD <.05 .35 (.134 to .898)
Overall survival
Minor H antigen matching .32 1.4 (.746 to 2.439)
Donor type .76 1.10 (.709 to 1.598)
GvHD .99 1.00 (.628 to 1.582)
Minor H antigen matching* GvHD <.05 .32 (.110 to .906)
Non-relapse mortality
Minor H antigen matching .46 1.23 (.711 to 2.137)
Donor type .14 1.33 (.912 to 1.933)
GvHD <.01 .63 (.390 to 1.019)
Minor H antigen matching* GvHD .46 .72 (.302 to 1.718)
GvHD indicates graft-versus-host disease.
For the analyses on the interaction between hematopoietic minor H antigen
mismatching and GvHD, P values lower than .10 were considered statisti-
cally signiﬁcant. For all other analyses, P values below .05 were used.
Hematopoieticminor H antigenmismatchingwas deﬁned as the presence of
at least 1 mismatch for a hematopoietic minor H antigen in GvL direction.
The current data set did not allow a triple interaction analysis including
donor type, minor H antigen mismatching, and GvHD status.
<.10 and <.05 indicate a P value from .05 to .10 and from .05 to .01
respectively.
* Interaction analyses have been performed for these 2 factors.
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that in the MUD recipients, a single HA-8 effect may not be
measurable. Alternatively, this effect may be explained by
the current different treatment of most MUD HSCT with
T cell depleted grafts. Our data set did not allow including
T cell depletion in the statistical analyses. It is important to
note that the group size for MUD was signiﬁcantly smaller
than the size of the IRD group. However, given the complete
overlap of the survival curves in Figure 3B, it is highly
unlikely that HA-8 matching in MUD leads to a signiﬁcant
increase in GvHD.An effect of the broadly expressed HLA-A1/HA-3
antigen on GvHD was not observed, though in unrelated
partially HLA-matched cornea transplantations, mismatch-
ing for HLA-A1/HA-3 was associated with rejection [35].
Although trends were seen in both the IRD and the MUD
study cohorts (Figure 3B), none of them were statistically
signiﬁcant. There was no interaction with donor type. These
analyses may, however, be hampered by the relatively low
phenotype frequency of HA-3, as only 10% of the HSCT pairs
had an HA-3 mismatch. The observed trends in the HLA-
mismatched cornea transplantation study and in the
present HSCT study justify a detailed study on larger cohorts
of HLA-A1-positive HSCT pairs in order to evaluate the role of
HA-3 in GVHD after IRD and/or MUD HSCT.
Finally, in our opinion, the most important observation
of this study is the signiﬁcant enhancing effect of hemato-
poietic minor H antigens on GvL. Notably, in line with an
earlier report on HA-1 [29], mismatching for hematopoietic
minor H antigens in patients suffering fromGvHD resulted in
a reduced relapse incidence (P ¼ .078), an increased relapse-
free survival (P < .05), and a better overall survival (P < .05).
All outcomes signiﬁcantly depended on the presence of
GvHD. This GvL effect of mismatching was absent in patients
who did not develop GvHD. The earlier observation by Mutis
et al. [29] was conﬁned to CML patients receiving HLA-
matched but HA-1-mismatched HSCT, using GvHD status of
the recipient as a binary variable. In the present cohort of
patients with various underlying diseases, the initial obser-
vation on HA-1 has been conﬁrmed for all hematopoietic
minor H antigens analyzed (Figure 5). More importantly, we
here included the GvHD status as a time-dependent variable,
showing a statistically signiﬁcant interaction between GvHD
and hematopoietic speciﬁc minor H antigens on relapse
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(Table 4). Although our data set did not allow analyzing this
triple interaction because of sample size, these effects seem
to be stronger in IRD HSCT than in MUD HSCT. Further
investigation on the role of donor type is of importance, as it
would yield information on the applicability of minor H
antigen-based immunotherapy in both IRD and MUD.
Controllable GvHD before or during such a therapy may well
be essential for the success of this approach. Indications
supporting the putative beneﬁcial effect of GvHD on the
antitumor reaction have been reported in a mouse study on
tumor-speciﬁc antigens, showing that tumor-speciﬁc T cells
develop most efﬁciently only under GvHD conditions [36].
Similar conclusions were drawn from the clinical observation
that WT1-speciﬁc CTL only emerged shortly after the
occurrence of GvHD, leading to the hypothesis that GvHD
stimulates the development and/or expansion of WT1-
speciﬁc CTL [37]. In line with these observations, develop-
ment of GvHD is crucial for the success of minor H antigen
vaccination in our currently ongoing phase 1 clinical trial
with multiple myeloma patients. Herein, recipient DCs,
instead of donor dendritic cells, are loaded with hemato-
poietic minor H peptides (Lokhorst, Mutis, Hambach,
Goulmy, unpublished results). In the latter study, we chose
for recipient dendritic cells as antigen-presenting cells to
induce a clinically relevant GvL effect. Because multiple
myeloma patients regularly fail to induce an adequate GvH
response, we assumed that recipients’ dendritic cells may
induce controllable GvHD alongside antiminor H antigen
T cell responses.
In conclusion, this study, executed under the auspices
of the IHIWwith the participation of 20 laboratories, enabled
statistical analyses of 10 autosomally and 10 Y-chromoso-
mally encoded minor H antigens on 849 HLA matched
patient/donor pairs for their presumed effects on the
outcome of HSCT. The present study comprised multiple
testing, analyzing the effect of various minor H antigens on
GVHD and relapse without formal correction for the number
of analyses. As such, the character of this study should be
regarded as indicative for the general inﬂuence of minor H
antigens on stem cell transplantation. The described obser-
vations, such as the effect of mismatching for broadly
expressed HA-8 on GvHD, thus require conﬁrmation on
dedicated cohorts. Notwithstanding the relatively small
number of hematopoietic minor H antigens analyzed, their
presumed role in the GvL response is endorsed. Our statis-
tical interaction analyses indicate that the latter response is
dependent on active anti-host responses after HSCT showing
signiﬁcant effects on relapse (P¼ .023), survival (P¼.069) and
relapse-free survival (P¼.025). These antileukemic responses
may be relevant information for the transplantation centers
that intend to apply minor H antigen-based immunotherapy
in HLA-matched hematopoietic minor H antigen-
mismatched transplantation recipients.ACKNOWLEDGMENTS
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